Pa., April 21 /PRNewswire-FirstCall/ -- NanoLogix,
Inc., (Pink Sheets: IFEC), a Nanobiotechnology
company engaged in the research, development and
commercialization of technologies for the production
of bacteria and disease testing kits, alternative
sources of fuel, cancer therapy and remediation
of toxic materials, announced the results of a
study which confirms that disseminated MAC and
M. simiae disease exist among AIDS patients. The
study was recently published in the Indian Journal
of Tuberculosis (Indian J Tuberc 2005; 52:21-26),
and a presentation made at the 58th National Conference
on Tuberculosis & Chest Diseases
held in Mumbai from 1st to 4th January, 2004.
Link for study: http://www.biotechstocksignals.com/ifecstudy.pdf
NanoLogix's "Identikit" has shown great
promise in detecting the presence of Mycobacterium
avium complex (MAC) infection. The methodology provides for early detection
of these pathogens in sputum and stool samples; thus allowing for treatment
before the infection spreads throughout the body. Early detection
of Mycobacterium avium complex (MAC) infection is
rapidly becoming important, especially for those with AIDS who are living longer
due to new methods of treatment. The study, conducted by a team in the Department
of Microbiology, Mahatma Gandhi Institute of Medical
Sciences, Sevagram between August 2001 and December
2002 was recently published. The team has documented that Mycobacterium avium
complex (MAC) infection was present in several patients with AIDS through the
testing of blood, sputum, peritoneal fluid, and stool samples with various
culturing, isolation and identification techniques and methods. Out of 167
patients tested positive for HIV, blood samples from 71 were cultured
for mycobacteria and 67 of these were also clinically
diagnosed as cases of either pulmonary and/or extrapulmonary tuberculosis.
The high prevalence of MAC infection in AIDS patients highlights the need for
a worldwide mandate to test AIDS patients using NanoLogix's Identikit.
NanoLogix recently announced that it has received
notification from the U.S. Food and Drug Administration
Center for Devices and Radiological Health ("FDA"),
of registration of the company and its initial product
line for biophasic system devices. Because it was categorized as a medical
device that did not require the standard lengthy FDA approval process,
NanoLogix is beginning the production, marketing and commercializing
of its Identikit biophasic system devices to cultivate
and identify certain pathogenic microorganisms for medical purposes.
MAC is the primary bacterial infection associated
with "wasting syndrome" of HIV/AIDS patients
and is the leading cause of death among these patients
worldwide. MAC is routinely resistant to anti-tuberculosis
drugs and there has been no standardized method for
determining antibiotic sensitivity. In HIV/AIDS patients,
MAC is usually diagnosed after symptoms appear. The
diagnostic screen utilizes a blood test. At this time,
mortality is very high and time to death is estimated
at four months. "With NanoLogix's Identikits,
MAC could be detected significantly sooner than expected
for normal culture techniques," stated Paul
Hyman, Ph.D. Dr. Hyman is the primary investigator
in NanoLogix's ongoing validation studies.
"Dr. Hyman's validation of NanoLogix's patented
technology and the subsequent FDA registration clearly
show that we can identify a costly disease in a fraction
of the time," commented Dr. Mitchell Felder,
Chief Executive Officer of NanoLogix. "These
results may also have enormous implications in the
treatment of TB, AIDS and MAC sufferers, as antibiotic-sensitivity
tests can now be performed early enough to make a
difference in these patients," he added.
According to estimates from the UNAIDS/WHO AIDS Epidemic
Update (December 2004), 37.2 million adults and 2.2
million children were living with HIV at the end of
2004. This is more than 50% higher than the figures
projected by WHO in 1991 on the basis of the data
then available. During 2004, some 4.9 million people
became infected with the human immunodeficiency virus
(HIV), which causes AIDS.
The year also saw 3.1 million deaths from AIDS - a
high global total, despite antiretroviral (ARV) therapy,
which reduced AIDS-related deaths in the richer countries.
Deaths among those already infected will continue
to increase for some years even if prevention programs
manage to cut the number of new infections to zero.
However, with the HIV-positive population still expanding
the annual number of AIDS deaths can be expected to
increase for many years, unless early diagnosis and
a more effective provision of ARV medication begins
to slow the death rate.
Published data shows that 30% of the individuals that
have HIV/Aids have Tuberculosis (TB). It has also
been estimated by world health authorities that more
than 70 percent of AIDS patients harbor an MAC infection.
It has been shown that MAC also causes opportunistic
infections among non-HIV infected pediatric and elderly
persons. NanoLogix's technology allows for the rapid
culturing and identification of MAC. It will also
provide viable treatment options by testing the particular
strain's antibiotic sensitivity. By using saliva or
stool samples, this process could identify an infection
as much as 10 months before the bacterium could be
found in blood samples and well before symptoms begin.
Tuberculosis kills more people each year than all
of the other infectious diseases combined and millions
of people will die this year because of TB. Tuberculosis
(TB) is a highly contagious disease transmitted through
the air contaminated with droplets released from the
lungs. TB strikes people in their most productive
years, ages 15 to 44. Of the 2 billion people infected
with TB, 200 million worldwide will develop active
TB and then be able to infect others. The key to controlling
the spread of TB is accurate and fast diagnosis so
that treatment can begin. Testing for TB has become
mandatory when related to immigration in most countries.
NanoLogix is very pleased with the sophisticated advances
in its Nanobiotechnology research and development
efforts in its day-to-day practice of medicine. A
complete report on NanoLogix can be found at: http://www.biotechstocksignals.com/ifec.pdf
NanoLogix, Inc., formerly known as InfectTech, Inc.
http://www.infectech.com/ , is a technology application
innovator of biogas products and services designed to assist in worldwide
energy independence and reduce pollution from renewable, environmentally-friendly
energy sources. NanoLogix is also engaged in the research and development
of diagnostic test kits designed to be used for the rapid identification
of infectious human diseases. The Company's patents span the identification
and antibiotic sensitivity testing of 34 disease-producing bacteria, including
M. tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas,
and nocardia. These bacteria are cited as prominent causes of morbidity
and mortality in patients with cancer, cystic fibrosis, and AIDS. Additionally,
NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer
cells utilizing hydrophobic hydrocarbons. Apoptosis is a
method for inducing a genetically based induction
of "cell suicide" in cells. The Company's
31 patents can be viewed by visiting http://www.infectech.com/intellectual_property.php
The convergence of science, medicine and technology
is on the cusp of yielding extraordinary breakthroughs.
Today, patents that were once designed to identify
bacteria have widespread applications across multiple
markets. At the heart of this convergence is nature.
All things begin and end with the building blocks
of life. NanoLogix's portfolio of 31 patents have
yielded a method vital to the development of biophasic
system devices intended for medical purposes to cultivate
and identify certain pathogenic microorganisms. The
devices contain one or more components that suppress
the growth of certain microorganisms while either
promoting or not affecting the growth of other microorganisms.
The FDA registered devices aid in the diagnosis of
disease caused by the pathogenic microorganisms. Additional
areas include: a method for low cost hydrogen production,
a genomic cancer therapy and methods for cleaning
up toxic environments using bioremediation.
NanoLogix's patents have nanotechnology applications
in medical drugs/devices, bio-defense sensors, hydrogen
production, cancer treatment and bioremediation. Nanotechnology applications
include Biochips embedded in small transportable devices for rapid bacteria
identification of disease causing pathogens, and Bio Micro Electro Mechanical
Systems ("BioMEMS") for rapid environmental
microbial monitoring with bio-defense implications.
Its hydrogen bioreactor research is designed to assist
in worldwide energy independence and reduce pollution
using renewable, environmentally-friendly energy sources.
NanoLogix's FDA registered diagnostic test kits are
designed to be used for the rapid identification of
infectious human diseases and identify 34 disease-producing
bacteria, including Tuberculosis (TB), Mycobacterium
avium-intracellulare (MAI), Pseudomonas, and Nocardia.
These bacteria are cited as prominent causes of morbidity
and mortality in patients with cancer, cystic fibrosis,
and AIDS, as well as in patients undergoing surgery.
Additionally, NanoLogix owns a patent for the nontoxic
induction of apoptosis in cancer cells utilizing hydrophobic
hydrocarbons. Apoptosis is a method for inducing a
genetically based induction of "cell suicide" in
cells. It therefore serves as the foundation for
cancer therapy. NanoLogix's other patents include
technology designed for use in the bioremediation
of contaminated soil and water.
CONTACT: Dr. Mitchell
S. Felder of NanoLogix, Inc., +1-724-346-1302
Web site: http://www.infectech.com/